Replimune gives an update on RP1 Clinical Development Program in CSCC
Category: #health  | By Mateen Dalal  | Date: 2019-10-17 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Replimune gives an update on RP1 Clinical Development Program in CSCC

Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer caused because of the uncontrolled growth of abnormal squamous cells. Currently, Libtayo is the only approved treatment in the Brazil and United States, and conditionally approved treatment in the Canada and European Union, for the treatment of locally advanced or metastatic CSCC.

Replimune Group Inc., a biotechnology company pioneering a new generation of oncolytic immuno-gene therapies, however, has reportedly announced that it has enrolled the first patient for its randomized, registration-directed, controlled Phase 2 clinical study of RP1.

The clinical study is being conducted in combination with Regeneron and Sanofi’s Libtayo® compared to Libtayo alone in patients who are suffering from CSCC.

Sources cite that initial data garnered from this clinical trial firmly supports the utility of RP1 in CSCC. Replimune has also announced its plan to begin another clinical trial of RP1 as monotherapy in organ transplant receiver with CSCC in early 2020.

According to Robert Coffin, Ph.D., CEO and President of Replimune, the company is delighted to announce the initiation of its first registration-directed clinical trial and data garnered for RP1 is strongly supportive.

Reportedly, the Phase 2 clinical study of RP1 is randomized, multi-center, and controlled clinical trial and is anticipated to register approximately 240 patients. Its main goal is to assess the response rate of RP1 with Libtayo against the response rate with Libtayo alone. This clinical study is conducted with Replimune’s collaboration agreement with Regeneron.

Reliable sources further claim that the full Phase 1 clinical efficacy, safety and biomarker data from this clinical trial, which Replimune expects will further support the overall clinical advancement strategy for RP1, is scheduled to be demonstrated at SITC (The Society For Immunotherapy of Cancer) Annual Meeting in National Harbor, Maryland on November 8, 2019.

Source Credit - https://www.biospace.com/article/releases/replimune-provides-update-on-rp1-clinical-development-program-in-cutaneous-squamous-cell-carcinoma/

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

By Mateen Dalal

American chemical company DuPont de Nemours Inc. reportedly signed a definitive agreement to buy out Spectrum Plastics Group from AEA Investors, a U.S. based private equity firm. The acquisition will reinforce DuPont’s position in booming non-c...